“Biopharmaceuticals are large and complex products isolated from genetically modified living organisms. Recently, biologics or biopharmaceuticals is one of the fastest growing sectors of pharmaceutical industries, owing to its innovative nature, greater safety and efficacy compared to traditional drugs.
The market for Biopharmaceutical is classified into three categories based on source, type of products and application areas, each of these segments are further broken down into sub-segments to give a comprehensive analysis of global biopharmaceuticals market.
The overall market has also been presented from the perspective of different geographic locations and key economies in this market. Competitors are highlighted and market players are profiled with attributes covering company overview, financial overview, business strategies, product portfolio and recent developments. Market shares of each of the prominent players for 2014 are detailed.
The market is largely dominated by North America which accounted for about half of the global share. APAC is a promising market and is opening gateways for new manufacturers.
The report also provides a detailed qualitative analysis of the factors responsible for driving and hindering the growth of the Biopharmaceuticals market and future opportunities that can propel the market.
The report contains the most detailed and in-depth segmentation and analysis of the Global Biopharmaceuticals Market during the forecast period 2014 – 2020.”
“1. Global Biopharmaceutical Market Overview
2. Executive Summary
3. Global Biopharmaceutical Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. Patent Analysis
3.2.3. End user profiling
3.2.4. Top 5 Financials Analysis
4. Global Biopharmaceutical Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Global Biopharmaceutical Market Strategic Analysis
5.1. Value Chain Analysis
5.2. Opportunities Analysis
5.3. Product lifecycle
5.4. Pricing Analysis
6. Global Biopharmaceutical Market- By Source
6.1. Unicellular System
6.1.1. Bacteria
6.1.2. Yeast
6.1.3. Insect
6.2. Multicellular System
6.2.1. Transgenic Plant
6.2.2. Transgenic Animal
7. Global Biopharmaceutical Market- By Products
7.1. Vaccines
7.2. Hormones
7.3. Enzymes
7.4. Blood
7.5. Blood Components
7.6. Monoclonal Antibodies
7.7. Growth Factors
7.8. Gene Therapies
7.9. Thrombolytics and Anticoagulants
7.10. Recombinant Therapeutic Protein
8. Global Biopharmaceutical Market- By Manufacturing Process
8.1. Single-Use System
8.2. Multi- Use System
9. Global Biopharmaceutical Market- By Application
9.1. Rheumatology
9.2. Oncology
9.3. Cardiology
9.4. Dermatology
9.5. Gastroenterology
9.6. Neurology
9.7. Others
10. Global Biopharmaceutical Market- By End Users
10.1. Biopharmaceutical Companies
10.2. Hospitals
10.3. Research Institutes
10.4. CROs
10.5. Diagnostic Labs
11. Global Biopharmaceutical Market -Geographic Analysis
11.1. North America
11.1.1. Canada
11.1.2. Mexico
11.1.3. USA
11.1.4. Others
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Sweden
11.2.5. U.K
11.2.6. Others
11.3. APAC
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia
11.3.5. Others
11.4. ROW
11.4.1. South Africa
11.4.2. South America
11.4.3. Russia
11.4.4. Saudi Arabia
11.4.5. Others
12. Market Entropy
12.1. New Product Launches
12.2. M&As, Collaborations, JVs and Partnerships
13. Company profiles
13.1. Johnson & Johnson Private Limited
13.2. Roche Holding AG
13.3. Abbott Laboratories
13.4. Bristol-Myers Squibb
13.5. Novartis International AG
13.6. Genentech Inc.
13.7. UCB
13.8. Merck Serono
13.9. Amgen
13.10. Eli Lilly & Co.
13.11. Biogen Idec
13.12. Merck KGaA
13.13. Élan Corporation
13.14. BioMarin Pharmaceutical Inc.
13.15. AbbVie Inc.
13.16. Invion Limited
13.17. AdAlta Pty Ltd.
13.18. Admedus Ltd
13.19. Biota Pharmaceuticals Inc.
13.20. Novozymes
13.21. Baxter International
13.22. APEIRON Biologics AG
13.23. Octapharma AG
13.24. Valneva SE
13.25. Genzyme
13.26. Mallinckrodt Pharmaceuticals
13.27. TM3 Therapeutics
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
“”*Financials would be provided on a best efforts basis for private companies””
14. Appendix
14.1. Abbreviations
14.2. Sources
14.3. Research Methodology
14.4. Bibliography
14.5. Compilation of Expert Insights
14.6. Disclaimer”
“13.1. Johnson & Johnson Private Limited
13.2. Roche Holding AG
13.3. Abbott Laboratories
13.4. Bristol-Myers Squibb
13.5. Novartis International AG
13.6. Genentech Inc.
13.7. UCB
13.8. Merck Serono
13.9. Amgen
13.10. Eli Lilly & Co.
13.11. Biogen Idec
13.12. Merck KGaA
13.13. Élan Corporation
13.14. BioMarin Pharmaceutical Inc.
13.15. AbbVie Inc.
13.16. Invion Limited
13.17. AdAlta Pty Ltd.
13.18. Admedus Ltd
13.19. Biota Pharmaceuticals Inc.
13.20. Novozymes
13.21. Baxter International
13.22. APEIRON Biologics AG
13.23. Octapharma AG
13.24. Valneva SE
13.25. Genzyme
13.26. Mallinckrodt Pharmaceuticals
13.27. TM3 Therapeutics”
